State of Wyoming Takes $567,000 Position in Guardant Health, Inc. $GH

State of Wyoming bought a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,890 shares of the company’s stock, valued at approximately $567,000.

A number of other large investors have also bought and sold shares of GH. Cetera Investment Advisers purchased a new stake in shares of Guardant Health during the first quarter valued at approximately $211,000. PNC Financial Services Group Inc. raised its holdings in Guardant Health by 25.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company’s stock valued at $112,000 after buying an additional 537 shares during the last quarter. Nuveen LLC purchased a new stake in Guardant Health during the 1st quarter valued at $3,151,000. HighTower Advisors LLC boosted its position in Guardant Health by 0.9% during the 1st quarter. HighTower Advisors LLC now owns 51,107 shares of the company’s stock valued at $2,177,000 after buying an additional 469 shares during the period. Finally, American Century Companies Inc. grew its holdings in Guardant Health by 0.3% in the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock worth $4,439,000 after acquiring an additional 282 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Trading Up 0.6%

NASDAQ GH opened at $102.67 on Tuesday. Guardant Health, Inc. has a 12 month low of $29.91 and a 12 month high of $112.43. The stock’s fifty day moving average price is $89.50 and its 200-day moving average price is $66.16. The stock has a market cap of $12.94 billion, a P/E ratio of -31.98 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.09. The business’s revenue was up 38.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.88) earnings per share. As a group, analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Michael Brian Bell sold 80,362 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $103.14, for a total transaction of $8,288,536.68. Following the completion of the sale, the chief financial officer owned 28,052 shares of the company’s stock, valued at $2,893,283.28. This trade represents a 74.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Amirali Talasaz sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $105.05, for a total value of $10,505,000.00. Following the completion of the transaction, the chief executive officer directly owned 168,223 shares in the company, valued at $17,671,826.15. This trade represents a 37.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 330,673 shares of company stock valued at $34,534,618. Company insiders own 6.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Mizuho set a $100.00 target price on shares of Guardant Health in a report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Wednesday, October 8th. Stifel Nicolaus set a $73.00 price objective on Guardant Health in a research report on Thursday, September 25th. Wolfe Research raised Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 target price on the stock in a research note on Thursday, September 25th. Finally, TD Cowen increased their price target on shares of Guardant Health from $63.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Twenty-three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average target price of $94.57.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.